Loading news...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK's growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV's long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma and depemokimab in severe asthma should extend GSK's specialty momentum. Additionally, GSK's late-stage pipeline includes 15 candidates targeting large TAMs. I like how Phase 3 CHB data is framed as a potential functional cure opportunity.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK'227), GSK's novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). “We believe exploring new mec.
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sales of the cancer drug Jemperli.
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exclusive License Agreement (“Collaboration Agreement”), which entitles Anaptys to receive royalties upon sales of Jemperli.
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--GSK licenses Noetik's AI foundation models in anchor partnership to transform cancer therapeutic research and development.
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B (CHB). The studies included over 1,800 patients.
GSK (GSK) just posted the kind of late-stage result drugmakers hope for. The company said its experimental hepatitis B treatment, bepirovirsen, delivered positi
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday that a potential new treatment for chronic hepatitis B had delivered positive late-stage trial results, raising the prospect of a shorter, more effective therapy for a disease that affects more than 250 million people worldwide. The drug, bepirovirsen, met its primary goal in two large phase III trials, B-Well 1 and B-Well 2, with GSK saying it achieved a “statistically significant and clinically meaningful” functional cure rate when added to existing treatment.
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday that a potential new treatment for chronic hepatitis B had delivered positive late-stage trial results,...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). The studies included over 1,800 patients from 29 countries. GSK licensed bepirovirsen from Ionis and the two companies have collaborated on its development. CHB is a ma.
GSK's experimental drug to treat chronic hepatitis B infection met the main goals in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step closer to making a functional cure available to patients.
GSK (GSK) notched a solid regulatory win in Japan, with health authorities approving Exdensur for patients with severe asthma and chronic rhinosinusitis with na
GSK PLC (LSE:GSK, NYSE:GSK) said Japan has approved Exdensur (depemokimab) to treat severe or refractory bronchial asthma and chronic rhinosinusitis with nasal polyps. The big-cap drugmaker said the authorisation was based on phase III SWIFT and ANCHOR trial data evaluating twice-yearly dosing versus placebo, each on top of standard of care.